Tagworks Pharmaceuticals
Manufacturing · Netherlands · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Toernooiveld 1, Nijmegen, Gelderland, 65...Phone Number
+31 858008550Website
www.tagworkspharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Tagworks Pharmaceuticals
Tagworks Pharmaceuticals is a pioneer in Click-to-Release technology, focusing on revolutionizing cancer treatment through in vivo click chemistry to enhance the efficacy and safety of systemic therapies. Their innovative approach aims to expand the therapeutic potential of antibody-drug conjugates (ADCs) and immunomodulators, targeting both on- and off-target effects in the tumor microenvironment. The company is led by a team of experienced researchers and oncologists dedicated to developing safe and effective treatments for cancer patients. Their pipeline includes advanced clinical trials for novel therapies such as TGW101 and TGW211, targeting specific cancer markers and improving treatment outcomes.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tagworks Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Tagworks Pharmaceuticals has new funding data
Tagworks Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tagworks Pharmaceuticals launches new products
Earning: See what the market has to say on Tagworks Pharmaceuticals recently announced quarterly report
Check out if Tagworks Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Tagworks Pharmaceuticals
Click to see if Tagworks Pharmaceuticals had a recent Job posting/layoffs
Check if Tagworks Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Tagworks Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Tagworks Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tagworks Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tagworks Pharmaceuticals.
Tagworks Pharmaceuticals financials insights
Gather financial insights about Tagworks Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$65M
Tagworks Pharmaceuticals Tech Stack
A closer look at the technologies used by Tagworks Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Project
Research & Development, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Regulations
Open Position
Tagworks Pharmaceuticals News & Media
Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks' proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination of...Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload...Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload...Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer
Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will continue in role of Chief Scientific Officer and as a member of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tagworks Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Tagworks Pharmaceuticals is a pioneer in Click-to-Release technology, focusing on revolutionizing cancer treatment through in vivo click chemistry to enhance the efficacy and safety of systemic therapies. Their innovative approach aims to expand the therapeutic potential of antibody-drug conjugates (ADCs) and immunomodulators, targeting both on- an... Read More
